Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.86 |
| ▸ | CTSD | P07339 | 3/20 | 0.86 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233672 | 1.00 | BACE1 (0.86) | BACE1CTSDBACE2 | |
| SCHEMBL8240837 | 0.94 | BACE1 (0.81) | BACE1CTSDBACE2 | |
| SCHEMBL4236948 | 0.92 | BACE1 (1.00) | BACE1CTSDBACE2 | |
| SCHEMBL8239023 | 0.92 | BACE1 (0.86) | BACE1CTSDBACE2 | |
| Trifluoroacetic Acid SCHEMBL4238296 | 0.92 | BACE1 (0.72) | BACE1CTSDBACE2 | |
| SCHEMBL5067087 | 0.91 | BACE1 (1.00) | BACE1CTSDBACE2 | |
| SCHEMBL4233968 | 0.91 | BACE1 (1.00) | BACE1CTSDBACE2 | |
| SCHEMBL8240480 | 0.88 | BACE1 (0.74) | BACE1CTSDBACE2 | |
| SCHEMBL8240407 | 0.88 | BACE1 (0.73) | BACE1CTSDBACE2 | |
| SCHEMBL8238880 | 0.86 | BACE1 (0.85) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954682-A1 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER S DISEASE, NEURODEGENERATION AND DEMENTIA | Astra Zeneca AB (SE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007058601-A1 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |